Kamada Ltd. (KMDA.TA)
KMDA.TA Stock Price Chart
Explore Kamada Ltd. interactive price chart. Choose custom timeframes to analyze KMDA.TA price movements and trends.
KMDA.TA Company Profile
Discover essential business fundamentals and corporate details for Kamada Ltd. (KMDA.TA) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
31 Aug 2005
Employees
420.00
Website
https://www.kamada.comCEO
Amir London
Description
Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis ; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.
KMDA.TA Financial Timeline
Browse a chronological timeline of Kamada Ltd. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 12 May 2026
Upcoming earnings on 3 Mar 2026
Upcoming earnings on 11 Nov 2025
Upcoming earnings on 12 Aug 2025
Revenue estimate is ILA 158.59M.
Earnings released on 14 May 2025
EPS came in at ILA 0.07 matching the estimated ILA 0.07, while revenue for the quarter reached ILA 164.68M, beating expectations by +1.94%.
Dividend declared on 17 Mar 2025
A dividend of ILA 71.01 per share was announced, adjusted to ILA 71.01. The dividend was paid on 7 Apr 2025.
Earnings released on 4 Mar 2025
EPS came in at ILA 0.07 surpassing the estimated ILA 0.05 by +40.00%, while revenue for the quarter reached ILA 141.80M, missing expectations by -7.16%.
Earnings released on 13 Nov 2024
EPS came in at ILA 0.07 matching the estimated ILA 0.07, while revenue for the quarter reached ILA 585.13M, beating expectations by +290.43%.
Earnings released on 14 Aug 2024
EPS came in at ILA 0.08 surpassing the estimated ILA 0.06 by +33.33%, while revenue for the quarter reached ILA 159.95M, beating expectations by +305.66%.
Earnings released on 8 May 2024
EPS came in at ILA 0.04 falling short of the estimated ILA 0.06 by -33.33%, while revenue for the quarter reached ILA 139.14M, beating expectations by +255.14%.
Earnings released on 6 Mar 2024
EPS came in at ILA 0.09 surpassing the estimated ILA 0.05 by +80.00%, while revenue for the quarter reached ILA 131.15M, missing expectations by -4.19%.
Earnings released on 13 Nov 2023
EPS came in at ILA 0.06 surpassing the estimated ILA 0.03 by +100.00%, while revenue for the quarter reached ILA 145.29M, beating expectations by +1.41%.
Earnings released on 16 Aug 2023
EPS came in at ILA 0.04 surpassing the estimated ILA 0.02 by +100.00%, while revenue for the quarter reached ILA 137.83M, beating expectations by +8.49%.
Earnings released on 24 May 2023
EPS came in at -ILA 0.04 falling short of the estimated -ILA 0.01 by -200.08%, while revenue for the quarter reached ILA 109.93M, missing expectations by -11.09%.
Earnings released on 15 Mar 2023
EPS came in at ILA 0.07 surpassing the estimated ILA 0.04 by +75.00%, while revenue for the quarter reached ILA 156.62M, missing expectations by -0.31%.
Earnings released on 22 Nov 2022
EPS came in at ILA 0.01 surpassing the estimated ILA 0.00 by +133.10%, while revenue for the quarter reached ILA 113.96M, beating expectations by +7.47%.
Earnings released on 19 Aug 2022
EPS came in at -ILA 0.09 falling short of the estimated -ILA 0.02 by -350.00%, while revenue for the quarter reached ILA 82.11M, missing expectations by -2.03%.
Earnings released on 17 May 2022
EPS came in at -ILA 0.04 falling short of the estimated -ILA 0.01 by -233.33%, while revenue for the quarter reached ILA 89.69M, beating expectations by +135.97%.
Earnings released on 15 Mar 2022
EPS came in at -ILA 0.11 falling short of the estimated -ILA 0.01 by -1.00K%, while revenue for the quarter reached ILA 97.71M, beating expectations by +41.41%.
Earnings released on 22 Nov 2021
EPS came in at -ILA 0.02 falling short of the estimated -ILA 0.01 by -180.11%, while revenue for the quarter reached ILA 74.12M.
Earnings released on 11 Aug 2021
EPS came in at ILA 0.02 falling short of the estimated ILA 0.05 by -60.00%, while revenue for the quarter reached ILA 79.04M.
Earnings released on 12 May 2021
EPS came in at ILA 0.06 surpassing the estimated ILA 0.05 by +20.00%, while revenue for the quarter reached ILA 82.89M.
Earnings released on 10 Feb 2021
EPS came in at ILA 0.04 falling short of the estimated ILA 0.07 by -42.86%, while revenue for the quarter reached ILA 101.34M.
Earnings released on 11 Nov 2020
EPS came in at ILA 0.15 surpassing the estimated ILA 0.08 by +87.50%, while revenue for the quarter reached ILA 121.05M.
Earnings released on 12 Aug 2020
EPS came in at ILA 0.08 falling short of the estimated ILA 0.12 by -33.33%, while revenue for the quarter reached ILA 114.06M.
KMDA.TA Stock Performance
Access detailed KMDA.TA performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.